Use of Protein kinase C delta binding protein (PRKCDBP) as a biomarker in patients with Ulcerative Colitis on Infliximab.
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2015
At a glance
- Drugs Infliximab (Primary)
- Indications Ulcerative colitis
- Focus Pharmacodynamics
- 18 Dec 2015 New trial record